2026-10-14T14:17:30Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34008345 2026-09-28T04:30:13Z category_393 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Real-world anatomical and functional outcomes following Faricimab therapy in neovascular age-related macular degeneration: a one-year observational study.docx Settimio Rossi (212323) Carlo Gesualdo (9133634) Maria Consiglia Trotta (6243830) Raffaele Perrotta (21516200) Fabiana Anna D'Agostino (25119432) Davide Sabbatino (25119435) Claudia Gerosolima (25119438) Rosalba Casaburi (25119441) Francesca Simonelli (139825) Foetal Development and Medicine Faricimab long-acting drugs neovascular age-related macular degeneration real-life outcomes treat-and-extend Introduction<p>This study evaluated 12-month anatomical and functional outcomes of Faricimab in Italian patients with neovascular age-related macular degeneration (nAMD).</p>Methods<p>30 eyes from 30 participants who completed the 12-month follow-up were retrospectively analyzed at “Luigi Vanvitelli” University Eye Clinic (Naples) and “Rummo” Hospital Ophthalmology Unit (Benevento). All underwent best-corrected visual acuity (BCVA), spectral-domain optical coherence tomography (SD-OCT), and optical coherence tomography angiography (OCTA). Patients were stratified by anti-vascular endothelial growth factor (VEGF) treatment [naïve (N = 22); non-naïve (N = 8)], baseline macular neovascularization (MNV) type and fluid distribution. BCVA and central retinal thickness (CRT) were assessed at 6 and 12 months. The association between baseline subretinal hyperreflective material (SHRM) status and longitudinal BCVA and CRT was also investigated.</p>Results<p>The intravitreal injection number was similar between naïve and non-naïve eyes (median, 6 vs. 7; p = 0.093). One adverse event (vitreitis with ocular hypertension) occurred. Mixed-effects modelling showed significant longitudinal improvements in BCVA from baseline to months 6 and 12, with no significant time-by-treatment-history interaction. Baseline retinal fluid distribution was not significantly associated with differences in BCVA changes, while baseline SHRM status showed a significant time-by-SHRM interaction for BCVA, although multiplicity-adjusted between-group comparisons were not significant at any time point. CRT decreased significantly from baseline to months 6 and 12, whereas the change between months 6 and 12 was not statistically significant. SHRM thickness also decreased significantly from baseline to months 6 and 12. Exploratory analyses by MNV subtype did not identify significant differences in 12-month BCVA or CRT. In exploratory multivariable analysis, baseline BCVA was the only factor significantly associated with 12-month BCVA, whereas age, previous anti-VEGF treatment, and baseline SHRM were not.</p>Discussion<p>This retrospective two-center study showed significant improvements in BCVA and CRT after 12 months of Faricimab, with no statistically detectable difference in longitudinal BCVA according to previous anti-VEGF exposure. Although baseline SHRM was associated with a significant time-by-SHRM interaction for BCVA, the absence of significant multiplicity-adjusted between-group differences limits interpretation of a differential response according to SHRM status. Given the small sample size and retrospective design, these findings should be interpreted cautiously.</p> 2026-09-28T04:30:13Z Dataset Dataset 10.3389/fmed.2026.1901385.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Real-world_anatomical_and_functional_outcomes_following_Faricimab_therapy_in_neovascular_age-related_macular_degeneration_a_one-year_observational_study_docx/34008345 CC BY 4.0